FIGURE 1



Plasma concentration (ng/mL)
250
200
150
100
50
0
0
6
12
18
24
Time (hr)
0.3 mg/kg
1 mg/kg
3 mg/kg
10 mg/kg

FIGURE 2

Time	Plasma concentration (ng/mL)			
(hr)	0.3 mg/kg	1 mg/kg	3 mg/kg	10 mg/kg
0.25	BLQ	BLQ	BLQ	BLQ
0.5	BLQ	BLQ	BLQ	BLQ
1	BLQ	BLQ	BLQ	BLQ
2	BLQ	BLQ	BLQ	BLQ
4	BLQ	BLQ	BLQ	BLQ
6	BLQ	BLQ	BLQ	BLQ
8	BLQ	BLQ	BLQ	BLQ
10	BLQ	BLQ	BLQ	BLQ
24	BLQ	BLQ	BLQ	BLQ

BLQ : below the lower limit of quantification (< 0.500 ng/mL)

3/11

Figure 3

	[illegible]	[illegible]	[illegible]
Summary statistics			
- n	385	385	388
- Median (hours)	73.2	102.3	81.6
- 95% confidence interval (hours)	67.2, 85.1	92.7, 113.1	69.4, 91.5
Comparison with Placebo			
- Median difference (hours)	-29.1	---	---
- 95% confidence interval for median difference (hours) [a]	-42.8, -14.6	---	---
- P-value derived from stratified generalized Wilcoxon test [b]	<0.0001	---	---
- P-value derived from stratified log-rank test [b]	0.0008	---	---
Comparison with Oseltamivir			
- Median difference (hours)	-7.7	---	---
- 95% confidence interval for median difference (hours) [a]	-22.7, 7.9	---	---
- P-value derived from stratified generalized Wilcoxon test [b]	0.8347	---	---
- P-value derived from stratified log-rank test [b]	0.8449	---	---

[a] Bootstrap estimates
[b] Stratification factors: region, composite symptom scores at baseline, and preexisting and worsened symptom
Patients who did not experience improvement of symptoms were treated as censored at the last observation time point.
Subset of patients whose time to improvement of symptoms were not missing

Figure 4



Proportion of Unimproved Patients
1.0
0.8
0.6
0.4
0.2
0.0
+ Censor
0
30
60
90
120
150
180
210
240
270
300
330
360
Time Since Start of Treatment (hours)
S-033188
Placebo
Oseltamivir


Figure 5

	DXM	Placebo	Oseltamivir
Summary statistics			
- n	166	167	148
- Median (hours)	74.6	100.6	101.6
Comparison with Placebo			
- Median difference (hours)	-26.0	---	---
- P-value derived from stratified generalized Wilcoxon test [a]	0.0138	---	---
Comparison with Oseltamivir			
- Median difference (hours)	-27.1	---	---
- P-value derived from stratified generalized Wilcoxon test [a]	0.0251	---	---

[a] Stratification factors: preexisting and worsened symptom and composite symptom scores at baseline
Patients who did not experience improvement of symptoms were treated as censored at the last observation time point.
Subset of patients whose time to improvement of symptoms were not missing

6/11

Figure 6


Proportion of Unimproved Patients
1.0
0.8
0.6
0.4
0.2
0.0
+ Censor
0
30
60
90
120
150
180
210
240
270
300
330
360
Time Since Start of Treatment (hours)
S-033188
Placebo
Oseltamivir

7/11

Figure 7

			[illegible]	Placebo	Oseltamivir
			[illegible]	[illegible]	[illegible]
High risk factor	Asthma or chronic lung disease	n	150 (38.7%)	156 (40.4%)	147 (37.8%)
		Median	**74.6 ***	**110.2**	**90.4**
	Endocrine disorders	n	122 (31.4%)	131 (33.9%)	128 (32.9%)
		Median	**73.2**	**100.8**	**91.2**
	Heart disease	n	45 (11.6%)	49 (12.7%)	53 (13.6%)
		Median	**67.1**	**92.2**	**103.7**
	More than or equal to 65 years of age	n	112 (28.9%)	102 (26.4%)	103 (26.5%)
		Median	**70.0**	**87.8**	**78.2**
	Metabolic disorders	n	50 (12.9%)	49 (12.7%)	56 (14.4%)
		Median	**56.8**	**57.4**	**45.7**
	Morbid obesity	n	36 (9.3%)	39 (10.1%)	47 (12.1%)
		Median	**88.3**	**112.8**	**97.5**

Unit of Median: hours, *: P< 0.05 (vs. Placebo)

8/11

Figure 8

		[illegible]	[illegible]	[illegible]
Patients with any complications	**Proportion**	**2.8% (11/388)**	**10.4% (40/386)**	**4.6% (18/389)**
	95% confidence interval (%)	**1.4, 5.0**	**7.5, 13.8**	**2.8, 7.2**
	Fisher's exact test			
	- P-value (vs Placebo)	**<.0001**	**---**	**---**
	- P-value (vs Oseltamivir)	0.2558	---	---
Death	Proportion	0.0% (0/388)	0.0% (0/386)	0.3% (1/389)
	95% confidence interval (%)	0.0, 0.9	0.0, 1.0	0.0, 1.4
	Fisher's exact test			
	- P-value (vs Placebo)	---	---	---
	- P-value (vs Oseltamivir)	1.0000	---	---
Hospitalization	Proportion	0.8% (3/388)	1.3% (5/386)	1.0% (4/389)
	95% confidence interval (%)	0.2, 2.2	0.4, 3.0	0.3, 2.6
	Fisher's exact test			
	- P-value (vs Placebo)	0.5047	---	---
	- P-value (vs Oseltamivir)	1.0000	---	---
Sinusitis	**Proportion**	**0.3% (1/388)**	**2.1% (8/386)**	**0.5% (2/389)**
	95% confidence interval (%)	**0.0, 1.4**	**0.9, 4.0**	**0.1, 1.8**
	Fisher's exact test			
	- P-value (vs Placebo)	**0.0285**	**---**	**---**
	- P-value (vs Oseltamivir)	1.0000	---	---
Otitis media	Proportion	0.0% (0/388)	0.8% (3/386)	0.3% (1/389)
	95% confidence interval (%)	0.0, 0.9	0.2, 2.3	0.0, 1.4
	Fisher's exact test			
	- P-value (vs Placebo)	0.1235	---	---
	- P-value (vs Oseltamivir)	1.0000	---	---
Bronchitis	**Proportion**	**1.8% (7/388)**	**6.0% (23/386)**	**2.3% (9/389)**
	95% confidence interval (%)	**0.7, 3.7**	**3.8, 8.8**	**1.1, 4.3**
	Fisher's exact test			
	- P-value (vs Placebo)	**0.0027**	**---**	**---**
	- P-value (vs Oseltamivir)	0.8016	---	---
Pneumonia	Proportion	0.0% (0/388)	0.8% (3/386)	0.5% (2/389)
	95% confidence interval (%)	0.0, 0.9	0.2, 2.3	0.1, 1.8
	Fisher's exact test			
	- P-value (vs Placebo)	0.1235	---	---
	- P-value (vs Oseltamivir)	0.4994	---	---

9/11

Figure 9

	[A]	[B]	[C]
Summary statistics			
- n	352	352	356
- Median (hours)	48.0	96.0	96.0
- 95% confidence interval (hours)	---	---	72.0, 96.0
Comparison with Placebo			
- Median difference (hours)	-48.0	---	---
- 95% confidence interval for median difference (hours) [a]	-48.0, -48.0	---	---
- P-value derived from stratified generalized Wilcoxon test [b]	< 0001	---	---
Comparison with Oseltamivir			
- Median difference (hours)	-48.0	---	---
- 95% confidence interval for median difference (hours) [a]	-48.0, -24.0	---	---
- P-value derived from stratified generalized Wilcoxon test [b]	< 0001	---	---

[a] Bootstrap estimates.
[b] Stratification factors: region, composite symptom scores at baseline, and preexisting and worsened symptom.
Patients whose influenza virus titer did not reach cessation were treated as censored at the last observation time point.
Patients whose influenza virus titer on Day 1 was positive and the time to cessation of viral shedding by influenza virus titer was not missing were included in this analysis.
One day was converted into 24 hours.

10/11

Figure 10

Time Point	Statistic	[redacted]	[redacted]	[redacted]
Day 2	n	336	343	344
	Mean	-3.36	-1.25	-1.76
	P-value (vs Placebo) derived from van Elteren test [a]	< 0001	---	---
	P-value (vs Oseltamivir) derived from van Elteren test [a]	<.0001	---	---
Day 3	n	338	336	340
	Mean	-3.92	-2.99	-3.26
	P-value (vs Placebo) derived from van Elteren test [a]	<.0001	---	---
	P-value (vs Oseltamivir) derived from van Elteren test [a]	0.0024	---	---
Day 4	n	130	121	124
	Mean	-3.99	-3.79	-3.75
	P-value (vs Placebo) derived from van Elteren test [a]	0.9127	---	---
	P-value (vs Oseltamivir) derived from van Elteren test [a]	0.5361	---	---
Day 5	n	326	321	333
	Mean	-4.32	-4.38	-4.41
	P-value (vs Placebo) derived from van Elteren test [a]	0.5739	---	---
	P-value (vs Oseltamivir) derived from van Elteren test [a]	0.5466	---	---
Day 6	n	115	105	105
	Mean	-4.07	-4.68	-4.39
	P-value (vs Placebo) derived from van Elteren test [a]	0.0543	---	---
	P-value (vs Oseltamivir) derived from van Elteren test [a]	0.4677	---	---
Day 9	n	327	320	322
	Mean	-4.53	-4.91	-4.78
	P-value (vs Placebo) derived from van Elteren test [a]	0.0266	---	---
	P-value (vs Oseltamivir) derived from van Elteren test [a]	0.1281	---	---

[a] Stratification factors: region, composite symptom scores at baseline and preexisting and worsened symptom.
Subset of patients who were positive for influenza virus titer at baseline
Day 1 was defined as the date of the first dose.

11/11

Figure 11

Study Week	Statistic	[illegible]	[illegible]	[illegible]
Day 2	n	150	154	133
	Mean	-2.85	-1.07	-0.97
	P-value (vs Placebo) derived from van Elteren test [a]	<.0001	---	---
	P-value (vs Oseltamivir) derived from van Elteren test [a]	<.0001	---	---
Day 3	n	148	150	131
	Mean	-3.63	-2.87	-2.52
	P-value (vs Placebo) derived from van Elteren test [a]	0.0074	---	---
	P-value (vs Oseltamivir) derived from van Elteren test [a]	0.0025	---	---
Day 4	n	56	53	46
	Mean	-4.21	-4.15	-3.37
	P-value (vs Placebo) derived from van Elteren test [a]	0.4410	---	---
	P-value (vs Oseltamivir) derived from van Elteren test [a]	0.0604	---	---
Day 5	n	145	145	126
	Mean	-4.41	-4.70	-4.51
	P-value (vs Placebo) derived from van Elteren test [a]	0.3962	---	---
	P-value (vs Oseltamivir) derived from van Elteren test [a]	0.8056	---	---
Day 6	n	52	47	41
	Mean	-4.61	-5.04	-4.63
	P-value (vs Placebo) derived from van Elteren test [a]	0.4113	---	---
	P-value (vs Oseltamivir) derived from van Elteren test [a]	0.5797	---	---
Day 9	n	145	145	123
	Mean	-4.76	-5.38	-5.02
	P-value (vs Placebo) derived from van Elteren test [a]	0.0350	---	---
	P-value (vs Oseltamivir) derived from van Elteren test [a]	0.3758	---	---

[a] Stratification factors: region, composite symptom scores at baseline and preexisting and worsened symptom.
Subset of patients who were positive for influenza virus titer at baseline
Day 1 was defined as the date of the first dose.